Utility of Serum Ratio of Heart-Type Fatty Acid-Binding Protein to Myoglobin for Cardiac Damage Regardless of Renal Dysfunction

Furuhashi, Masato; Ura, Nobuyuki; Hasegawa, Kôichi; Tsuchihashi, Kazufumi; Nakata, Tomoaki; Shimamoto, Kazuaki

doi:10.1253/circj.68.656

Cited by 8 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 89 FABP4 level is significantly higher in females than in males, possibly because of the larger amount of body fat in females than in males since there is an independent and strong correlation between FABP4 level and adiposity. 89 , 90 Consistent with the results of previous studies showing that levels of several FABPs were increased in subjects with renal dysfunction, 84 , 91 , 92 serum FABP4 level was shown to be negatively correlated with estimated glomerular filtration rate in recent studies, 89 , 93 suggesting that FABPs are eliminated from the circulation mainly by renal clearance. We previously showed that FABP4 level in hemodialysis patients with end-stage kidney disease was about 20 times higher than that in controls with normal renal function and was decreased by 57.2% after hemodialysis.…”

Section: Circulating Concentration Of Fabp4 As a Potent Biomarkersupporting

confidence: 87%

Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases

Furuhashi

Saitoh

Shimamoto

et al. 2014

Clin Med Insights Cardiol

Self Cite

306

315

View full text Add to dashboard Cite

Over the past decade, evidences of an integration of metabolic and inflammatory pathways, referred to as metaflammation in several aspects of metabolic syndrome, have been accumulating. Fatty acid-binding protein 4 (FABP4), also known as adipocyte FABP (A-FABP) or aP2, is mainly expressed in adipocytes and macrophages and plays an important role in the development of insulin resistance and atherosclerosis in relation to metaflammation. Despite lack of a typical secretory signal peptide, FABP4 has been shown to be released from adipocytes in a non-classical pathway associated with lipolysis, possibly acting as an adipokine. Elevation of circulating FABP4 levels is associated with obesity, insulin resistance, diabetes mellitus, hypertension, cardiac dysfunction, atherosclerosis, and cardiovascular events. Furthermore, ectopic expression and function of FABP4 in several types of cells and tissues have been recently demonstrated. Here, we discuss both the significant role of FABP4 in pathophysiological insights and its usefulness as a biomarker of metabolic and cardiovascular diseases.

show abstract

Section: Circulating Concentration Of Fabp4 As a Potent Biomarkersupporting

confidence: 87%

Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases

Furuhashi

Saitoh

Shimamoto

et al. 2014

Clin Med Insights Cardiol

Self Cite

306

315

View full text Add to dashboard Cite

show abstract

“…In addition, some studies reported that serum concentrations of H-FABP or A-FABP are increased in ESRD patients on HD compared to those in control subjects with normal renal function (41424344). However, there are only 2 published studies that investigated L-FABP levels in chronic kidney disease (CKD).…”

Section: Discussionmentioning

confidence: 99%

Cytokine-like Activity of Liver Type Fatty Acid Binding Protein (L-FABP) Inducing Inflammatory Cytokine Interleukin-6

et al. 2016

View full text Add to dashboard Cite

It has been reported that fatty acid binding proteins (FABPs) do not act only as intracellular mediators of lipid responses but also have extracellular functions. This study aimed to investigate whether extracellular liver type (L)-FABP has a biological activity and to determined serum L-FABP levels in patients with end-stage renal disease (ESRD). We isolated L-FABP complementary deoxyribonucleic acid (cDNA) from the Huh7 human hepatocarcinoma cell line and expressed the recombinant L-FABP protein in Escherichia coli. A549 lung carcinoma and THP-1 monocytic cells were stimulated with the human recombinant L-FABP. Human whole blood cells were also treated with the human recombinant L-FABP or interleukin (IL)-1α. IL-6 levels were measured in cell culture supernatants using IL-6 enzyme-linked immunosorbent assay (ELISA). Human recombinant L-FABP induced IL-6 in a dose-dependent manner in A549, THP-1 cells, and whole blood cells. The blood samples of healthy volunteers and patients with ESRD were taken after an overnight fast. The serum levels of L-FABP in healthy volunteers and ESRD patients were quantified with L-FABP ELISA. The values of L-FABP in patients with ESRD were significantly lower than those in the control group. Our results demonstrated the biological activity of L-FABP in human cells suggesting L-FABP can be a mediator of inflammation.

show abstract

“…A ratio of 5 is considered specific for the heart and a ratio ranging from 21 to 70 is more suggestive of skeletal muscle damage [45]. Recently, this ratio has been found useful in patients with renal dysfunction by Furuhashi et al [58], who identified a hFABP/myoglobin ratio value of 0.147 as the cut-off level for cardiac involvement. Other authors have questioned the advantages of the myoglobin/hFABP ratio as a useful test for acute ischemic injury detection [45, 56, 59].…”

Section: Hfabpmentioning

confidence: 99%

Heart Fatty Acid Binding Protein in the Diagnosis of Myocardial Infarction: Where Do We Stand Today?

Colli¹,

Josa²,

Pomar³

et al. 2006

Cardiology

View full text Add to dashboard Cite

Heart fatty acid binding protein (hFABP) is a novel small cytosolic protein that is abundant in the heart. It is highly cardiac-specific (i.e. expressed primarily in cardiac tissue), but is also expressed at low concentrations in tissues outside the heart. After myocardial ischemic damage, hFABP can be detected in the blood as early as 1–3 h after onset of chest pain, with peak values reached at 6–8 h and plasma levels returning to normal within 24–30 h. hFABP’s clinical diagnostic value is very limited in the presence of renal failure and skeletal muscle diseases as it is completely renally eliminated. In these conditions, the diagnosis of acute myocardial infarction (AMI) may be overestimated. The combination of initial hFABP release after symptom onset, rapid kidney clearance from the circulation and high cardiac specificity suggests great potential for clinical use. Serial measurements of hFABP in the first 24 h after onset of symptoms in AMI patients can: (a) identify patients who are susceptible to reperfusion strategies, (b) detect perioperative AMIs, (c) distinguish patients who reperfuse their infarct-related artery from those who do not, as early as 30 min after starting thrombolytic treatment, (d) detect re-infarction if it occurs within 10 h after symptom onset, and (e) permit an accurate estimation of myocardial infarct size providing important prognosis information.

show abstract

Utility of Serum Ratio of Heart-Type Fatty Acid-Binding Protein to Myoglobin for Cardiac Damage Regardless of Renal Dysfunction

Cited by 8 publications

References 17 publications

Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases

Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases

Cytokine-like Activity of Liver Type Fatty Acid Binding Protein (L-FABP) Inducing Inflammatory Cytokine Interleukin-6

Heart Fatty Acid Binding Protein in the Diagnosis of Myocardial Infarction: Where Do We Stand Today?

Contact Info

Product

Resources

About